Latest news and press releases about Veracyte, Inc. (VCYT): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis.
Price
| Price | $45.81 |
| Market Cap | $3.7B |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| P/E Ratio | 32.72 |
| Price / Book | 2.63 |
| EV / EBITDA | 26.17 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | 8.64% |
| Return on Invested Capital | 6.70% |
| Return on Assets | 7.70% |
| Gross Margin | 72.09% |
| Operating Margin | 17.03% |
| Net Margin | 20.37% |
Related companies: ADPT · IDYA · IRON · KNSA · LEGN
Explore sector: Healthcare · Medical - Diagnostics & Research
More sections of VCYT: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Investment Academy — learn to analyze stocks